key: cord-0889362-jt6xtree
authors: Chen, Wen-Hsiang; Pollet, Jeroen; Strych, Ulrich; Lee, Jungsoon; Liu, Zhuyun; Kundu, Rakhi Tyagi; Versteeg, Leroy; Villar, Maria Jose; Adhikari, Rakesh; Wei, Junfei; Poveda, Cristina; Keegan, Brian; Bailey, Aaron Oakley; Chen, Yi-Lin; Gillespie, Portia M.; Kimata, Jason T.; Zhan, Bin; Hotez, Peter J.; Bottazzi, Maria Elena
title: Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
date: 2021-10-21
journal: Protein Expr Purif
DOI: 10.1016/j.pep.2021.106003
sha: 332da3d63bacf39d7f7d82063f46ccdec1b0257e
doc_id: 889362
cord_uid: jt6xtree

SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple manufacturers to address the global vaccine equity gap, and need for low-cost, easy to scale, safe, and effective COVID-19 vaccines. In this paper, we report on the generation of the receptor-binding domain RBD203-N1 yeast expression construct, which produces a recombinant protein capable of eliciting a robust immune response and protection in mice against SARS-CoV-2 challenge infections. The RBD203-N1 antigen was expressed in the yeast Pichia pastoris X33. After fermentation at the 5 L scale, the protein was purified by hydrophobic interaction chromatography followed by anion exchange chromatography. The purified protein was characterized biophysically and biochemically, and after its formulation, the immunogenicity was evaluated in mice. Sera were evaluated for their efficacy using a SARS-CoV-2 pseudovirus assay. The RBD203-N1 protein was expressed with a yield of 492.9 ± 3.0 mg/L of fermentation supernatant. A two-step purification process produced a >96% pure protein with a recovery rate of 55 ± 3% (total yield of purified protein: 270.5 ± 13.2 mg/L fermentation supernatant). The protein was characterized to be a homogeneous monomer that showed a well-defined secondary structure, was thermally stable, antigenic, and when adjuvanted on Alhydrogel in the presence of CpG it was immunogenic and induced high levels of neutralizing antibodies against SARS-CoV-2 pseudovirus. The characteristics of the RBD203-N1 protein-based vaccine show that this candidate is another well suited RBD-based construct for technology transfer to manufacturing entities and feasibility of transition into the clinic to evaluate its immunogenicity and safety in humans.

In this paper, we report on the generation of the receptor-binding domain RBD203-N1 yeast expression 23 construct, which produces a recombinant protein capable of eliciting a robust immune response and 24 protection in mice against SARS-CoV-2 challenge infections. The RBD203-N1 antigen was expressed in the 25 yeast Pichia pastoris X33. After fermentation at the 5 L scale, the protein was purified by hydrophobic 26 interaction chromatography followed by anion exchange chromatography. The purified protein was 27 characterized biophysically and biochemically, and after its formulation, the immunogenicity was 28 evaluated in mice. Sera were evaluated for their efficacy using a SARS-CoV-2 pseudovirus assay. The 29 RBD203-N1 protein was expressed with a yield of 492.9 ± 3.0 mg/L of fermentation supernatant. A two-30 step purification process produced a >96% pure protein with a recovery rate of 55 ± 3% (total yield of 31 purified protein: 270.5 ± 13.2 mg/L fermentation supernatant). The protein was characterized to be a 32 homogeneous monomer that showed a well-defined secondary structure, was thermally stable, antigenic, 33 and when adjuvanted on Alhydrogel in the presence of CpG it was immunogenic and induced high levels 34 of neutralizing antibodies against SARS-CoV-2 pseudovirus. The characteristics of the RBD203-N1 protein-35 based vaccine show that this candidate is another well suited RBD-based construct for technology transfer 36 to manufacturing entities and feasibility of transition into the clinic to evaluate its immunogenicity and 37 safety in humans. 38 with 100 µL 2 µg/mL of either RBD203-N1 or RBD219-N1C1 overnight in duplicate at 4°C followed by 119 blocking with PBST/0.1% BSA overnight at 4°C. Once the plates were blocked, 100 µL 3x serially-diluted 120 mAb with an initial concentration of 2 µg/mL was added to the wells. The plates were incubated at room 121 temperature for 2 hours to allow mAb to bind to RBDs. After this binding step, the plates were washed 122 with PBST four times followed by adding 100 µL 1:6,000 diluted HRP conjugated anti-mouse IgG antibodies 123 (LSBiosciences) and incubated for 1 hour at room temperature. Finally, 100 µL TMB substrate was added 124 and incubated for 4 minutes in the dark to react with HRP. The reaction was terminated with 100 µL of 125 1M HCl and absorption readings were taken at 450 nm using a BioTek EPOCH 2 microplate reader. 126

Waters Alliance HPLC Separations Modules and Associated PDA Detectors were operated as per the 128 vendor's instruction. Fifty micrograms of Bio-Rad gel filtration standard or RBD203-N1 were injected into 129 a TSKgel® G2000SWXL column (300 mm X 7.8 mm), and eluted in 20 mM Tris, 150 mM NaCl, pH 7.5 (1X 130 TBS) at the flow rate of 0.6 mL/min. 131

The size of RBD203-N1 in solution was analyzed using DLS. Briefly, the concentration of the protein was 133 adjusted to 1 mg/mL using 1X TBS. The samples were then filtered through 0.02 μm filters. Four replicates 134 of forty microliters of protein were loaded into each well of a clear bottom 384-well plate. The 135 hydrodynamic radii of the proteins were measured using a DynaPro Plate Reader II. 136

Purified RBDs were diluted with deionized water to a final concentration of 0.2 mg/mL and loaded into a 138 0.1 cm path cuvette. Dilution with water was to reduce the chloride ion content, which is known to 139 J o u r n a l P r e -p r o o f interfere with the CD absorbance, especially at low wavelengths. CD spectra were obtained from 250 to 140 190 nm with a Jasco J-1500 spectrophotometer set at 100 nm/min and a response time of 1 s at 25°C. The 141 CD data were analyzed using a CD Analysis and Plotting Tool (https://capito.uni-jena.de/index.php). In 142 addition, the RBDs (0.5 mg/mL) were heated from 25 °C to 95 °C for a denaturation profile analysis. 143

RBD203-N1 or RBD219-N1C1 were diluted to 0.32 mg/mL and mixed with the reagents in Protein Thermal 145

Shift™ Dye kit (Thermo Fisher) as per the vendor's instructions. In short, 12.5 µL of 0.32 mg/mL RBD were 146 mixed with 5 µL of Protein Thermal Shift buffer, followed by 2.5 µL of 8x Protein Thermal Shift dye in three 147 to four replicates. These samples were vortexed briefly and centrifuged to remove any bubbles and 148 further heated from 25 °C to 95 °C to monitor the change of fluorescence intensity at 623±14 nm after 149 excitation at 580 ±10 nm using a ViiA™ 7 Real-Time PCR system. 150

Ninety-six-well ELISA plates were coated with 100 µL 5 µg/mL ACE-2-hFc (LakePharma) overnight at 4°C 152 followed by blocking with PBST/0.1% BSA. Once the plates were blocked, 100 µL serially diluted RBD219-153 N1C1 or RBD203-N1 with an initial concentration of 40 µg/mL were added to the wells. The plates were 154 incubated at room temperature for 2 hours to allow ACE-2 to interact with each RBD. After this binding 155 step, the plates were washed with PBST four times followed by adding 100 µL of 1:5,000 diluted anti-156 RBD219-WT horse sera followed by 1:10,000 diluted HRP conjugated anti-horse IgG antibodies and 157 incubating for 1 hour at room temperature. Finally, 100 µL TMB substrate were added and incubated for 158 15 min in the dark to react with HRP. The reaction was terminated with 100 µL of 1M HCl and absorption 159 readings were taken at 450 nm using a BioTek EPOCH 2 microplate reader. To examine RBD-specific antibodies in mouse sera, indirect ELISAs were conducted as described previously 171

[13]. Briefly, 96-well ELISA plates were coated with 100 µL of 2 µg/mL RBDs in 1x coating buffer and 172 incubated overnight at 4 °C. The plates were then blocked with 200 µL/well PBST/0.1% BSA for 2 hours at 173 room temperature. After being washed once with 300 µL PBST. 100 µL of serially diluted mouse serum 174 samples, naïve mouse serum, and blank (PBST/0.1% BSA) were added to the plate and incubated for 2 175 hours at room temperature. The plates were further washed four times with PBST and dispensed with 176 100 µL of 1:6,000 diluted goat anti-mouse IgG HRP for 1 hour at room temperature, followed by washing 177 five times with PBST. Finally, 100 µL TMB substrate were added to each well and incubated for 15 minutes 178 at room temperature. After incubation, the reaction was stopped by adding 100 µL of 1 M HCl. The 179 absorbance at a wavelength of 450 nm was measured using a BioTek Epoch 2 spectrophotometer. 180

Splenocytes preparation and cytokine measurements were performed as previously described [13] . Briefly, 182

GentleMACS Octo Dissociator was used to dissociate spleen and pelleted splenocytes. The splenocytes 183 were then resuspended in 1 mL ACK lysing buffer for 1 minute at room temperature followed by the 184 addition of 40 mL PBS. Splenocytes were again pelleted and resuspended in 5 mL 4°C cRPMI (RPMI 1640 185 + 10% HI FBS + 1x pen/strep) and transferred through a 40 µm filter to obtain a single-cell suspension. 186

For the in vitro cytokine release assay, splenocytes were seeded in a 96-well culture plate at 1×10 6 To evaluate the reproducibility of the production process, two identical 5L scale production runs were 219 performed. During production, the yield and the recovery were monitored ( Table 1 ). The results indicated 220 a fermentation yield for RBD203-N1 of 492.9 ± 3.0 mg/L of fermentation supernatant (FS) with an overall 221 recovery of 55 ± 3% after purification. When evaluating the coefficient of variation of the process, one 222 could notice that the %CV was lower than 6% throughout the process, indicating that the process was 223

reproducible. Purity analysis of the in-process samples (Figure 2A) revealed that the downstream process 224 efficiently improved the purity from 61.8 ± 1.1% to 97.0 ± 0.4% under reduced conditions, or from 75.0 ± 225 0.6% to 96.4 ± 0.9% under non-reduced conditions. SE-HPLC data also revealed the purity of RBD203-N1 226 was approximately 99.9% (Figure 2B) . Additionally, DLS indicated that RBD203-N1 was monodispersed 227 (5.9% Polydispersity) with an estimated molecular weight of 31 kDa (Figure 2C) . The antigenicity of RBD203-N1 against 8 different in-house generated anti-SARS-CoV-2 RBD219-WT 231 monoclonal antibodies were evaluated using western blot with RBD219-N1C1 as a control (Figure 3) . 232

Overall, the binding profile of the antibodies to RBD203-N1 and RBD219-N1C1 was similar. Neutralizing 233 antibodies (mAbs 1128, 643, and 486) likely recognized conformational epitopes and thus did not 234 recognize reduced RBDs well. mAbs 854 and 942 recognized both non-reduced and reduced RBD equally, 235 while mAbs 748 and 102 recognized the reduced RBDs stronger than the reduced RBDs. Although 203 236 dimer was not detectable in SDS-PAGE, SE-HPLC, these monoclonal antibodies all recognized the RBD203 237 dimer form. Interestingly, mAb486 only recognized the RBD dimer but not the monomer, suggesting that 238 the dimer form might have better preserved the conformation for antibody recognition. 239

Similar to the western blot, ELISAs were performed using the same monoclonal panel against 240 RBD203-N1 and RBD219-N1C1, respectively. Similar binding profiles were observed for both proteins for 241 seven of the eight mAbs in a native condition. With mAb-486, a slightly lower affinity to RBD203-N1 was 242 observed (Figure 4) . 243 244 245

When far-UV CD spectrometry was performed to investigate the secondary structure of RBD203-N1 in 247 comparison with RBD219-N1C1, we observed very similar data ( Figure 5A) . The thermal stability of the 248 secondary structures was evaluated by heating the samples from 25 °C to 95 °C (Figures 5B-5C ) and CD 249 melting curves and their derivatives were further examined at 231 nm ( Figures. 5D-5E) . Based on the 250 derivative, the average melting temperatures (Tm) were 50.8 °C and 51.9 °C for RBD203-N1 and RBD219-251 N1C1, respectively, suggesting similar thermal stability. 252 253 254

In this study, we used thermal shift assays to compare the thermal stability of the tertiary structure for 256 RBD203-N1 and RBD219-N1C1. The melting curve ( Figure 6A) showed a similar fluorescence profile 257 between these two RBDs. The initial fluorescence of both proteins indicated similar surface hydrophobicity 258 when they were still intact. When the temperature was increased, these two proteins started to denature 259 (Ton) at approximately 38 °C. Calculated from the derivatives, the melting temperatures (Tm) were 50.4. ± 260 0.6 °C and 50.7 ± 0.2 °C for RBD203-N1 and RBD219-N1C1, respectively (Figure 6B) , which further 261 suggested that these two RBDs shared similar tertiary structures. 262 263 J o u r n a l P r e -p r o o f

Li et al. have indicated that the most potent neutralizing antibodies that recognized the RBD blocked its 265 binding to ACE-2 [14] and thus, confirming the ability of RBD to bind to ACE-2 is crucial. When comparing 266 RBD203-N1 and RBD219-N1C1 in this way, both RBDs bound to ACE-2 similarly with EC50 values of 0.0417 267 ± 0.005 µg/mL and 0.0410 ± 0.004 µg/mL, respectively (Figure 7) . 268 269 3.6. RBD203-N1 formulated with alum/CpG triggered strong immunity and neutralizing activity 270

The study design to evaluate the immunogenicity and neutralizing activity is shown in Figure 8A [10], when formulated with alum alone, secretion of IFN-gamma, IL-6, and IL-10 was observed, while the 278 addition of CpG produced a stronger and more balanced Th1/Th2 response, with increased levels of IL-2, 279 IL-4, IL-6 and IFN-gamma( Figure 8C) . 280

When neutralizing capacity was evaluated in a pseudovirus assay (Figure 8D) , no neutralizing 281 antibodies were detected in the sera of mice immunized twice with RBD203-N1/alum, RBD219-N1C1/alum, 282 alum, and alum+CpG. However, mice immunized with two doses of RBD203-N1 or RBD219-N1C1 (7 g) 283 formulated with alum+CpG showed approximately 2.5-fold higher neutralizing antibody titers than the 284 National Institute for Biological Standards and Control (NIBSC) human convalescent plasma standard. No 285 significant differences in the titers were observed between mice immunized with RBD203-N1 or RBD219-286 N1C1, formulated alum+CpG. Collectively, the data suggest that RBD203-N1 and RBD219-N1C1 elicit 287 similar levels of antigen-specific antibodies, neutralizing antibodies, and cytokines. Here we report on an alternative COVID-19 vaccine candidate antigen based on a truncated receptor-291 binding domain construct of the SARS-CoV-2 spike protein. The antigen, RBD203-N1, containing residues 292 332-533 of the RBD domain, is a truncated version of RBD219-N1C1 containing residues 332-549. 293 RBD203-N1was expressed effectively in the yeast P. pastoris and purified by a combination of hydrophobic 294 interaction chromatography and anion exchange chromatography. The fermentation yield was 295 determined as 492.9 ± 3.0 mg RBD203-N1/L of FS, which was a 42% increase over RBD219-N1C1 [12]. The 296 overall recovery from this two-step purification scheme for RBD203-N1 was determined as 55 ± 3%, a 41% 297 increase of the process yield (39%) for RBD219-N1C1 [12] . The production process was demonstrated to 298 be reproducible with less than 6% of %CV throughout the process between two identical production runs. 299 RBD203-N1 was shown to be a protein of high purity when analyzed by SDS-PAGE (>96%) and SE-HPLC 300 (>99%). DLS also indicated that the purified protein was monodispersed. When we inspected the 301 molecular weight of the deglycosylated RBD203-N1 by mass spectrometry (Supplementary method and  302 Supplementary Figure 1) , we discovered two major RBD203-N1 species with additional EAEAEF or EAEF 303 amino acid residues at the N-terminus. The EAEA residues are expected remnants due to well-described 304 inefficient P. pastoris Ste13-protease cleavage of the signal peptide upstream of recombinant proteins 305 expressed in the pPICZ/P. pastoris system [15] . The adjacent EF residues are derived from the translation 306 of the EcoRI used for cloning of the RBD sequence in pPICz Nevertheless, the different purified RBD203-307 N1 lots were consistently 82-85% of the EAEAEF-variant and 15-18% of the EAEF-variant again proving 308 the reproducibility of the production process. 309

We further assessed the biophysical and biochemical characteristics of RBD203-N1 by evaluating 310 its antigenicity, secondary structure, thermal stability, and in vitro functionality. When eight in-house 311 monoclonal antibodies, generated against the wild-type RBD219 (no deletion of N or C) [8, 9] were used 312 to evaluate the antigenicity of these two RBDs by western blot and ELISA, both RBDs were recognized 313 mostly to the same extent. One exception was mAb486 that only recognized the dimer form of RBD203-314 N1 in the western blot, which suggested that the dimer form might have preserved the confirmation 315 better. When assessing the secondary structures, far-UV CD spectra indicated that RBD203-N1 and 316 RBD219-N1C1 proteins had similar secondary structures and the melting temperatures evaluated by CD 317 further revealed that the thermal stability for the secondary structure of both proteins was comparable. 318

Additionally, thermal shift assays also indicated that both RBDs shared comparable thermal stability for 319 their tertiary structures. Moreover, the in vitro functionality assay further confirmed a similar binding 320 J o u r n a l P r e -p r o o f affinity to ACE-2 to these RBDs, suggesting that these two RBDs shared the same biophysical and 321 biochemical characteristics. 322

The immunogenicity in mice of RBD203-N1, when formulated with alum with or without the TLR9 323 agonist CpG, was evaluated. The addition of CpG to COVID-19 vaccine formulations has been 324 demonstrated to promote antigen dose sparing as well as the induction of balanced Th1/Th2 immune 325 responses with much lower intra-cohort variability [13] . When adjuvanted with CpG, the use of 7ug and 326 2.3ug of RBD203-N1 protein elicited robust neutralizing antibody titers that were protective against SARS-327

CoV-2 pseudovirus particles. The level of neutralizing antibodies in the serum was 2.5-times higher than 328 the NIBSC standard plasma and was also equivalent to the control RBD219-N1C1/alum+CpG vaccine [13] . 329

The use of low RBD protein concentration, when formulated with alum alone and in a two-dose regime, 330 did not trigger robust antigen-specific antibody titers and the neutralizing activity was undetectable. 331

However, our studies with RBD/alum formulations in two-or three-dose regimens using higher protein 332 doses have been shown to trigger robust immune responses with high neutralizing titers [10]. In addition, 333

Nanogen, recently showed that their Nanocovax vaccine, consisting of a recombinant S protein 334 formulated with alum was immunogenic and efficacious in various animal models [16] . Therefore, RBD 335 proteins, including RBD203-N1, adjuvanted with alum alone should continue to be evaluated for safety, 336 immunogenicity and efficacy especially in the context of the changing SARS CoV-2 virus epidemiology, or 337 as a potential booster immunization for other COVID-19 vaccine platforms. 338

In this study, we report on RBD203-N1, a truncated version of the SARS CoV-2 spike protein RBD. The 340 fermentation yield of this construct was 493 mg/L of FS. The two-step purification process allowed for a 341 recovery of more than 50% of RBD203-N1. The purified RBD203-N1 was of high purity (>96% by SDS-PAGE 342 and >99% by SE-HPLC). When studying the biophysical and biochemical characteristics, we confirmed this 343 truncated protein retained the expected secondary structure, thermal stability, antigenicity, and 344 functionality. Additionally, when formulated with alum+CpG, it triggered a robust level of antigen-specific 345 antibodies that possess neutralizing ability, as well as a desired balanced cytokine profile. Collectively, the 346 data suggested that RBD203-N1 (like the RBD219-N1C1 construct [9, 10]) is a suitable COVID-19 vaccine 347 candidate antigen for technology transfer and transition into the clinic to evaluate its safety, 348 immunogenicity, and efficacy in humans. 349 

Breaking evolution's chains: the prospect of deliberate genetic 375 modification in humans

A Brief Reminder of Systems of Production and 377 Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals

Yeast-based vaccines: New perspective in vaccine development and 380 application

Emerging Technologies for Low-Cost, Rapid Vaccine 382 Manufacture

Structural and functional comparison of SARS-CoV-2-spike receptor 384 binding domain produced in Pichia pastoris and mammalian cells

A modular protein subunit vaccine candidate produced in yeast confers protection 390 against SARS-CoV-2 in non-human primates. bioRxiv (2021)

A yeast expressed RBD-based SARS-CoV-2 397 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor 402 binding domain as a COVID-19 vaccine candidate

SARSCoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant 406 receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity 407 in mice

Optimization of the Production 410 Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain 411 (RBD219-N1), a SARS Vaccine Candidate

Process development and scale-up optimization of the SARS-CoV-2 414 receptor binding domain-based vaccine candidate, RBD219-N1C1

Receptor-binding domain recombinant protein RBD219-N1C1 on alum-CpG induces 419 broad protection against SARS-CoV-2 variants of concern

Potent neutralizing antibodies against multiple epitopes on SARS-423

CoV-2 spike

Heterologous protein expression in the methylotrophic yeast Pichia 425 pastoris